Do you want to read an article? Please log in or register.
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial
Lung Cancer
Related content
RECOMMENDED
Lung Cancer
Real-world frontline treatments in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor exon 20 insertions and adjusted comparisons versus amivantamab plus chemotherapy from the PAPILLON study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Chouaid C, Bosquet L, Knott C, Li Z, Schaeffer M, Lin X, Schioppa CA, Perualila NJ, Diels J, Caparros EQ, Galea F, Hultén A, Greystoke A
doi: 10.1016/j.lungcan.2025.108548
Lung Cancer
First-line serplulimab plus chemotherapy with or without HLX04 versus chemotherapy in locally advanced or metastatic non-squamous non-small-cell lung cancer (ASTRUM-002): a randomised, double-blind, multicentre phase 3 trial
Lancet Respir Med
Wang L, Hao X, Hao Y, Hu Y, Chen C, Chen B, Huang Y, Zang A, Wang Y, Chen Z, Zhuang W, Shi J, Ren X, Nie L, Yu G, Luo F, Mao Y, Wang X, Li B, Bai Y, Shi J, Ni H, Yu H, Li J, Wang Q, Zhu J, Shi Y, ASTRUM-002 Study Group
doi: 10.1016/S2213-2600(25)00263-2
Lung Cancer
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Lancet Respir Med
Shi Y, Wu L, Ji Y, Chen G, Li B, Bi M, Yang R, Miao L, Zhang G, Gao H, Sun L, Zhang M, Cang S, Sun M, Yao W, Pan Z, Cui J, Xiao Y, Wang Q, NCT04143607 Study Group
doi: 10.1016/S2213-2600(25)00121-3
Lung Cancer
Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)
Nat Commun
Shen B, Wang C, Zhang L, Zhu Y, Zhang X, Wang X, Guo Z, Wang L, Wang X, Zhu L, Zhou Y, Liao D, Shi M
doi: 10.1038/s41467-026-68554-6
Lung Cancer
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial
Nat Commun
Zeng L, Ruan Z, Yan H, Qin H, Zeng Z, Zou C, Huang Z, Jiang W, Dai J, Xu S, Song L, Chen Y, Zhang Y, Zeng F, Wei S, Chen S, Liu L, Xiong Y, Wang Z, Deng J, Zhang X, Sun Y, Yang D, Zhou C, Yang H, Li Y, Deng L, Xu Q, Fang C, Chen X, Wang J, Li T, Zhang G, Zhou H, Yang N, Zhang Y
doi: 10.1038/s41467-025-67262-x
Lung Cancer
A Patient-Centric, Open-Label, Multicenter, Phase II Study of Lorlatinib Monotherapy in the First-Line Treatment of Patients With locally Advanced or Metastatic ALK-Positive Non-Small Cell Lung Cancer (CTONG2203)
Clin Lung Cancer
Lin JX, Zhou Q, Yan HH, Liu AW, Wu GW, Chu Q, Du YY, Cui JW, Cheng Y, Yang Y, Xu HP, Tu HY, Wu YL, Liu SM
doi: 10.1016/j.cllc.2025.05.014
Lung Cancer
Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials
Lung Cancer
Zhou DD, Lord SJ, Lin FP, Cooper WA, Zaheed M, Simes RJ, John T, Lee CK
doi: 10.1016/j.lungcan.2025.108891
RECOMMENDED
Lung Cancer
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Nat Commun
Bian D, Ji S, Liu Y, Huang Z, Jiang L, Liu M, Bao X, Yang J, Zhou Y, Hu J, Sun L, Zheng Y, Huang J, Liu J, Zhu X, Zhang J, Zhang L, Liu X, He W, Xie D, Zhu Y, Wu C, Zhao D, Duan L, Jiang G, Zhang P
doi: 10.1038/s41467-025-58435-9
Lung Cancer
Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS)
Clin Lung Cancer
Sakata Y, Saito G, Sakata S, Yamaguchi T, Tamiya M, Suzuki H, Shibaki R, Okada A, Yokoyama T, Matsumoto H, Otsuki T, Sato Y, Uchida J, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T
doi: 10.1016/j.cllc.2025.05.015